Loading...
  • clinical
  • Participants were followed up monthly for a period of six months by hormonal (FSH, LH and E2), clinical (resuming menstruation), US (folliculometry), histopathological (HP), and IH expression of stem cell marker OCT4 of the endometrial biopsy (stem cell positivity according to ESS) outcome. (clinicaltrials.gov)
  • immunomodulatory
  • A randomized study regarding with statistical power to evaluate the clinical outcome of autologous HSCT compared to a standard immunomodulatory treatment in MS has not yet been published. (clinicaltrials.gov)
  • Immunomodulatory properties of the agent include activation of T cells and natural killer cells, increased numbers of natural killer T cells, and inhibition of proinflammatory cytokines (eg, tumor necrosis factor-α and interleukin-6) by monocytes. (ascopost.com)
  • months after transplantation
  • After a median follow-up of 72 (60-80) months, 18 (82%) patients achieved completed remission, one (5%) patient achieved partial remission, and one patient had no response and received peritoneal dialysis at 12 months after transplantation. (asnjournals.org)
  • Patients will be followed by Evaluation of EDSS MSFC RAO Test brain and cervical MRI and quality of life questionnaire after 1th 3th 6th and 12th months after transplantation.all these tests will be done before transplantation as basic evaluation. (clinicaltrials.gov)
  • Lymphoma
  • In order to improve the clinical result of high-dose chemotherapy and autologous stem cell transplantation for B-cell non-Hodgkin's lymphoma, Zevalin will be added to the conditioning regi. (bioportfolio.com)
  • It may contain different types of non-Hodgkin lymphoma cells or both Hodgkin and non-Hodgkin lymphoma cells. (bioportfolio.com)
  • A form of non-Hodgkin lymphoma having a usually diffuse pattern with both small and medium lymphocytes and small cleaved cells. (bioportfolio.com)
  • Stem cell transplantation strategies are typically considered in the setting of ______________ indolent lymphoma. (mdedge.com)
  • Extranodal natural killer (NK)/T cell lymphoma, nasal type, is a recently recognized distinct entity and the most common type of non-B cell extranodal lymphoma in Asia. (nih.gov)
  • A total of 47 patients from 3 previously published series of HSCT were matched according to NK/T cell lymphoma International Prognostic Index (NKIPI) risk groups and disease status at transplantation with 107 patients from a historical control group for analysis. (nih.gov)
  • PCL is histologically characterized by a mostly diffuse large B-cell lymphoma. (springer.com)
  • Primary cardiac diffuse large B-cell lymphoma: diagnosis by transesophageal echocardiography-guided transvenous biopsy. (springer.com)
  • CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. (springer.com)
  • At diagnosis, non-Hodgkin lymphoma patients had a median age of 45 (range: 8-65) years old, 78% had diffuse large B-cell lymphoma and 83% had stage III/IV disease. (scielo.br)
  • 1,2 The drug was previously approved to treat multiple myeloma (in combination with dexamethasone), anemia caused by del(5q)-related myelodysplastic syndromes, and relapsed mantle cell lymphoma. (ascopost.com)
  • It inhibits proliferation and induces apoptosis of certain hematopoietic tumor cells, including mantle cell lymphoma, multiple myeloma, and del(5q) myelodysplastic syndrome in vitro and delays tumor growth in hematopoietic tumor models including multiple myeloma. (ascopost.com)
  • hematologic recovery
  • 65 years who had undergone induction therapy followed by stem cell transplant and had achieved at least a stable disease response at the time of hematologic recovery were eligible. (ascopost.com)